More diverse, more global.
Using a vast range of technology to deliver health.

Taiyo Pharma Tech has provided the stable contracted manufacturing of high-quality medical pharmaceuticals for over 80 years. In October 2019, we launched new operations as a Group company of chemical manufacturer Taiyo Holdings Co., Ltd.


The Taiyo Holdings Group is a chemical manufacturer that is among the world’s leading companies for solder resist, a critical element in the printed circuit boards used in all types of electronics. Embracing the management philosophy of “achieving a cheerful society by further advancing every technology in our Group and by creating a wide range of innovative products to fulfill the dreams of the world,” the Taiyo Holdings Group continues to achieve dynamic growth in various domains.
One of those domains is the medical and pharmaceutical business, which is growing into a major business for the Group. Working together with Taiyo Pharma, which is engaged in the manufacturing and sales of pharmaceutical products, Taiyo Pharma Tech will engage this medical and pharmaceutical business.


Taiyo Pharma Tech is a contract development and manufacturing organization (CDMO) that effectively utilizes the advanced technical strengths and production capacity of the Takatsuki Plant, our manufacturing base, to innovate all aspects of our technology. To strengthen our functions as a contract manufacturing organization (CMO), not only do we work to strengthen our domestic manufacturing, but we are also establishing a global production structure to ensure our ability to provide high-quality products.
And to take the next step forward, we will expand beyond CMO operations to become a CDMO as we diversify operations in the medical and pharmaceutical business by engaging in domains such as regenerative medicine and gene therapy.


We will continue to utilize all kinds of continuously innovating technology to proactively engage in new operations in order to respond to the diverse needs of pharmaceutical companies in Japan and around the world and contribute to healthy outcomes for a great many patients.

Eiji Sato, President and CEO